The European Commission’s probe into suspected anti-trust activity in the pharmaceutical sector is rumbling on, with further dawn raids earlier this week.
Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.